Author

Erwin Pardo

Observed institution: Sanofi (United States)

OpenAlex ID: A5112999932

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

2023 · Gustavo H Dayan, Nadine Rouphael, et al. · The Lancet Respiratory Medicine · 25

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data

2025 · Leah I. B. Andrews, M. Elizabeth Halloran, et al. · JAMA Network Open · 6

Works count: 2

Citation count: 31

H-index: 2

I10-index: 1